Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Redhill Biophrma ADR (NQ: RDHL )

0.3840 +0.0040 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Redhill Biophrma ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb
Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also fell, dropping 0.60% to 4,441.76. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5... 
Via Benzinga
Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide
Midway through trading Tuesday, the Dow traded down 0.49% to 34,698.16 while the NASDAQ fell 0.05% to 15,098.38. The S&P also fell, dropping 0.24% to 4,458.05. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares... 
Via Benzinga
Cantor Sees 'Compelling Investment Opportunity' In This Biopharma
Cantor Fitzgerald has 
Via Benzinga
Why RedHill Biopharma Stock Is Getting Crushed Today
A clinical failure is sending shareholders to the exits this morning. 
Via The Motley Fool
Exposures COVID-19
Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August
Following the market opening Tuesday, the Dow traded down 0.26% to 34,778.27 while the NASDAQ rose 0.01% to 15,106.84. The S&P also fell, dropping 0.20% to 4,459.89. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Happening With RedHill Biopharma's Stock On Tuesday?
RedHill Biopharma Ltd (NASDAQ: RDHL) announced preliminary top-line data from Phase 2/3 study evaluating opaganib in hospitalized patients with severe COVID-19... 
Via Benzinga
RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa
Regulatory authorities in South Africa have signed off RedHill Biopharma Ltd's (NASDAQ: RDHL) Phase 2/3 study evaluating RHB-107 (upamostat) for non-... 
Via Benzinga
Exposures COVID-19
RHB-107 P2/3 COVID-19 Study South Africa Approval
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
RedHill Unveils New Movantik Data For Opioid-Induced Constipation
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses. The three analyses included pooled data from two Phase 3... 
Via Benzinga
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
RedHill to Present at HCW & Cantor Conferences
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / September 2, 2021 / RedHill Biopharma... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers INmune Bio (NASDAQ:INMB) shares ... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. (NASDAQ: ELYS) rose 43% to close at $6.62 after it... 
Via Benzinga
Why RedHill Biopharma Stock Jumped on Tuesday
An analyst on Wall Street thinks the company's commercial and development pipeline has been underestimated. 
Via The Motley Fool
33 Stocks Moving In Tuesday's Mid-Day Session
Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of Roche Holdings, announced topline data from Phase 2... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2021
Upgrades For GoodRx Holdings Inc (NASDAQ:GDRX),... 
Via Benzinga
Mid-Morning Market Update: Markets Edge Lower; Designer Brands Earnings Top Estimates
Following the market opening Tuesday, the Dow traded down 0.04% to 35,387.11 while the NASDAQ fell 0.30% to 15,219.57. The S&P also fell, dropping 0.12% to 4,523.41. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Regional Health Properties Inc (NYSE: RHE) rose 50.3% to $12.49 in pre-market trading after jumping over 15% on Monday. The company, earlier during the month, reported Q2... 
Via Benzinga
RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib. Related: ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) stock increased by 22.69% to $151.73 during Thursday's pre-market session. The company's market cap stands at $8.1 billion.... 
Via Benzinga
Redhill Biopharma: Q2 Earnings Insights
Shares of Redhill Biopharma (NASDAQ:RDHL) rose 11.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 250.00%... 
Via Benzinga
RedHill Reports Second Quarter 2021 Results
- Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 -... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance Supply Chain
Exposures COVID-19 Intellectual Property Legal
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model,... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Earnings Scheduled For August 26, 2021
Companies Reporting Before The Bell • Gambling.com Gr (NASDAQ:GAMB) is likely to report quarterly earnings at $0.07 per share on revenue of $10.38 million. •... 
Via Benzinga
A Preview Of Redhill Biopharma's Earnings
Redhill Biopharma (NASDAQ:RDHL) will be releasing its next round of earnings this Thursday, August 26. For all of the relevant information, here is your guide for Thursday's Q2... 
Via Benzinga
RedHill Announces Two New U.S. Patents
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.